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Abstract We describe a P2X subunit cloned from the zebrafish
(Danio rerio) that is an orthologue of the mammalian P2X3
subunit. Like the mammalian P2X3, this receptor desensitizes
rapidly in the presence of agonist. However, it differs in that
KL-meATP is a much less potent agonist than ATP and the
antagonist TNP-ATP is not active at low nanomolar concentra-
tions. Similar to the rat P2X3 subunit, the zebrafish subunit
forms hetero-oligomeric assemblies with the rat P2X2 that
possesses a phenotype distinct from either parent. This novel
clone will provide an important basis for future experiments
investigating the structure/function relationships of P2X subunit
domains. ß 2000 Federation of European Biochemical Socie-
ties. Published by Elsevier Science B.V. All rights reserved.
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1. Introduction
Accumulating evidence demonstrates that ATP can act as
an extracellular signal in a number of tissues via its activation
of cell surface receptors (for review, see [1]). There are at least
two classes of ATP receptors; the G-protein-coupled receptors
labeled P2Y and the ligand-gated ionotropic receptors named
P2X [2]. The P2X receptors are non-selective cation channels
that show appreciable permeability to Ca2 [3]. Initial electro-
physiological and pharmacological studies suggested the exis-
tence of multiple P2X receptor subtypes (for example, see [4])
and this has been borne out by the recent cloning of seven
distinct mammalian genes encoding P2X receptor proteins [5].
Each of the seven mammalian subunits, when recombinantly
expressed as homo-oligomers, displays a unique pro¢le with
regards to their pharmacological and biophysical pro¢les [6].
The predicted amino acid sequences of the seven mamma-
lian P2X receptor subunits exhibit a moderate degree (approx-
imately 35^50% when the intracellular C-terminus is excluded)
of identity amongst themselves. The disparities in their amino
acid sequences are thought to underlie their functional di¡er-
ences with regards to both pharmacological and biophysical
properties. We sought to exploit this phenomenon by cloning
orthologues of the mammalian proteins from more disparate
species in anticipation that evolutionary divergence would be
manifested in the primary sequences and that this in turn
would yield subunit proteins with novel properties. Such dif-
ferences could then be utilized for the elucidation of the de-
terminants underlying such important receptor properties as
ligand speci¢city and channel kinetics. To this end, we sought
to identify subunit cDNAs from a lower vertebrate, the zebra-
¢sh (Danio rerio). We accomplished this through the use of
virtual screening of the EST database. In this report, we show
that a novel zebra¢sh cDNA encodes a P2X3 subunit ortho-
logue. This subunit is capable of forming both homo- and
hetero-oligomeric receptors and does indeed possess function-
al properties quite di¡erent from the mammalian orthologue,
suggesting that characterization of such evolutionarily diver-
gent genes will provide a useful framework for future experi-
ments investigating the structure/function relationships of
P2X receptors.
2. Materials and methods
2.1. Molecular biology
A TBLASTN search of the GenBank EST database using the pre-
dicted amino acid sequence of the rat P2X5 subunit identi¢ed the
zebra¢sh EST clone fb99b08 (accession number AI588766) as possibly
encoding a P2X receptor subunit. This plasmid was obtained from
Research Genetics Inc. (Huntsville, AL, USA) and after sequencing
both strands using the Terminator kit from US Biochemical (Cleve-
land, OH, USA) was found to contain the complete coding sequence
for a zebra¢sh orthologue of the P2X3 subunit (see Fig. 1). The se-
quence for this clone has been deposited in the GenBank and has the
accession number AF238292. For engineering of an expression con-
struct, the coding region was obtained by PCR using primers £anked
by EcoRI and XhoI restriction sites and subcloned into the mamma-
lian expression vector pCDNA-3.1 (Invitrogen, Carlsbad, CA, USA).
2.2. Transfection of HEK-293 cells
HEK-293 cells were transiently transfected with the P2X receptor
cDNA(s) by incubating cells grown on 35 mm plates with 1 Wg of total
cDNA and 6 Wl of lipofectamine (Gibco BRL, Gaithersburg, MD,
USA) in 1 ml of serum-free medium (Opti-MEM, Gibco BRL). After
5 h at 37‡C, the medium was replaced with complete minimal essential
medium and cells were incubated for 40^48 h (as per [7]).
2.3. Electrophysiological recordings
Whole-cell current was recorded from single HEK-293 cells using
the perforated-patch, whole-cell, voltage-clamp technique [8]. Low re-
sistance (1^2 M6) electrodes were ¢lled with 0.3 mg/ml amphotericin
B dissolved in an intracellular solution of the following composition
(in mM): 130 Cs methanesulfonate, 24 CsCl, 10 HEPES, 1 CaCl2 and
1 MgCl2. The extracellular solution was (in mM): 154 NaCl,
2.0 CaCl2, 1 MgCl2, 10 glucose, 10 HEPES, pH 7.3 with NaOH.
Membrane current recording started when the series resistance fell
to less than 10 M6. The typical holding voltage was 340 mV where
the e¡ect of ATP was generation of an inward current. Current^volt-
age curves were generated by measuring current during a 100 ms
voltage ramp from 360 to 60 mV. Currents caused by voltage ramps
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recorded in the absence of ATP were subtracted from those recorded
during ATP application to isolate the drug-induced current. In all
experiments, drugs were applied by manually moving the electrode
and attached cell into the line of £ow of solutions exiting an array
of inlet tubes.
3. Results and discussion
Screening of the EST database with the rat P2X5 primary
sequence identi¢ed a zebra¢sh EST clone (fb99b08) (Washing-
ton University Zebra¢sh EST Project), which when sequenced
revealed an open reading frame encoding a protein of 410
amino acids. Alignment of the predicted amino acid sequence
of this clone with those of the seven members of the rat sub-
unit family using the Clustal X program [9] demonstrated that
it was most similar to the rP2X3 subunit (a comparison is
shown in Fig. 1) and thus we tentatively designated this new
clone as zP2X3. The primary sequence exhibits many hall-
marks of the mammalian P2X subunit sequences: the inferred
topology is the same, the 10 conserved extracellular cysteine
residues are present, and it has 63 of the 71 amino acids that
are completely positionally conserved throughout the seven
mammalian proteins. The nine residues that di¡er in the ze-
bra¢sh are H54, R156, V179, N236, L239, T243, A312, E316
and V329, which are tyrosine, threonine, alanine, phenylala-
nine, alanine, glycine, aspartate and isoleucine residues, re-
spectively, in the mammalian subunits.
Expression of zP2X3 in HEK-293 cells resulted in ATP-
induced inward currents, as seen in Fig. 2. The observed cur-
rent was similar to those obtained at the rat P2X1 and P2X3
receptors [10,11] in two ways. First, zP2X3 receptors desensi-
tized rapidly in the continued presence of agonist with the
time course of desensitization varying from cell to cell,
although concentrations of ATP greater than about 1 WM
always caused a near complete desensitization within a few
(v 3) seconds. Second, closely spaced applications of ATP
led to a progressive loss of ATP-gated currents (Fig. 2).
Most importantly, the zebra¢sh clone exhibited a marked
lengthening in resensitization time when compared to its
mammalian orthologue, as it required a minimum of 30 min
to recover completely from a single application of ATP versus
approximately 15 min for the rat P2X3 (data not shown).
The biophysical properties of zP2X3 were examined using a
low concentration of ATP in order to have a slower desensi-
Fig. 1. Comparison of the primary sequences of the zebra¢sh and
rat P2X3 subunits. Alignment was carried out using the Clustal X
program [9]. Common residues are boxed. Sequence is in GenBank,
accession number AF238292.
Fig. 2. Desensitization of ATP-gated current. ATP (3 WM) was ap-
plied every 5 min to an HEK-293 cell transiently expressing zP2X3
receptors. Four consecutive traces are shown. The ¢rst application
of ATP caused a large, rapidly desensitizing inward current. Subse-
quent applications evoked smaller currents. In this and all subse-
quent ¢gures, the dotted line indicates the zero current level.
Fig. 3. Current^voltage relationship for the zP2X3 receptor. A: A
low concentration (300 nM) of ATP evoked an inward current that
desensitized little during a short (about 2 s) application of agonist.
The lack of desensitization permitted current^voltage curves to be
generated using the voltage ramp protocol described in the text.
B: Current^voltage relationship for the zP2X3. The current reverses
at 3 mV and shows pronounced inward recti¢cation.
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tization (Fig. 3A). Results from these experiments are consis-
tent with the properties seen for the mammalian P2X subunits
in that the channel exhibits non-selective cation permeability
(reversal potential slightly positive of zero, Fig. 3B) and has a
pronounced inward recti¢cation (Fig. 3B).
The next step was to examine the basic pharmacological
pro¢le of zP2X3. Due to the prolonged resensitization time
of the receptor, dose^response curves were generated by mea-
suring the e¡ect of di¡erent concentrations of ATP applied at
30 min intervals. ATP often caused variable sized currents to
the same concentration of agonist even when applied infre-
quently and therefore the data included in our estimation of
the EC50 of ATP came only from those cells that showed a
clear dose^response relationship. Data from individual cells
were normalized to the e¡ect of 3 WM ATP in that cell. The
normalized data were then pooled and subsequently ¢t to the
Hill equation using Igor (Wavemetrics, OR, USA). Analysis
of dose^response experiments (Fig. 4A) gave an EC50 for ATP
of 1.5 þ 0.5 WM with a Hill slope of 1.6 (pooled data obtained
from eight cells), values similar to that seen for rP2X3 ([11]
and our unpublished results). Unexpectedly, zP2X3 demon-
strated a pharmacological pro¢le di¡erent from its mamma-
lian cognate as the ATP analogue KL-meATP, which is equi-
potent to ATP at rP2X3 [11], was much less potent at the
zebra¢sh homo-oligomeric receptor (Fig. 4B). In addition,
the analogue TNP-ATP, which is a potent antagonist at
rP2X3 (an IC50 of approximately 1 nM [12]), had no e¡ect
on 1 WM ATP-induced currents at zP2X3 when co-applied at a
concentration of 3 nM (Fig. 4C). In parallel experiments, we
veri¢ed that this concentration of TNP-ATP was su⁄cient to
block ATP’s actions at the recombinant rP2X3 receptor (data
not shown).
Another attribute of rP2X subunits is their ability, in most
part, to co-assemble with one another to form hetero-oligo-
meric receptors [13]. In some cases, the hetero-oligomers ex-
hibit novel properties when compared to the parent homo-
oligomers [11,7]. We therefore sought to determine if the
zP2X3 subunit could also participate in hetero-oligomeric re-
ceptor formation. With the mammalian receptors, a combina-
tion of special interest has been the rP2X2=3 hetero-oligomer,
which is thought to be a prevalent receptor subtype on sen-
sory neurons [11,14]. A distinguishing characteristic of this
particular hetero-oligomeric receptor is that it exhibits the
pharmacological pro¢le of the rP2X3 subunit (KL-meATP sen-
sitive whereas the rP2X2 subunit is insensitive to this ana-
logue) but the desensitization kinetics of the rP2X2 subunit
(very slow in comparison to rP2X3). As the zP2X2 subunit is
not yet available, we tested whether zP2X3 could form a het-
ero-oligomeric receptor with rP2X2. As seen in Fig. 5, a low
concentration of ATP induced slowly desensitizing currents in
cells co-transfected with rP2X2 and zP2X3 (left trace). When
10 WM KL-meATP was applied 2 min following the ATP
administration, a smaller slowly desensitizing current was ob-
served (middle trace); a result which is in keeping with the
relative potencies of these two drugs at the zP2X3 homo-oli-
gomeric receptor. Two minutes after the KL-meATP treat-
ment, 1 WM ATP was again administered and a current sim-
ilar in size to that seen with the ¢rst ATP dose was observed
(right trace). These results demonstrate that hetero-oligomeric
receptors were formed and present. This interpretation is
based on two facts: ¢rst, that the homo-oligomeric zP2X3
desensitizes so quickly and resensitizes so slowly (see Fig. 1)
that with only 2 min between drug applications neither the
KL-meATP response nor the second ATP current would have
been present to any extent if co-assembly had not occurred,
and second, that the KL-meATP current could not arise from
Fig. 4. Pharmacological pro¢le of the zP2X3 receptor. A: Inward
currents evoked by four di¡erent concentrations of ATP. Lower
concentrations evoked smaller currents that desensitize slowly. High-
er concentrations yield larger currents that desensitize quickly. ATP
was applied once every 30 min. B: A single application of 30 WM
KL-meATP was bracketed by applications of 3 WM ATP. The larger
concentration of KL-meATP evoked smaller currents than the lower
concentrations of ATP. Drugs were applied at 30 min intervals. C:
3 nM TNP-ATP failed to block the current evoked by ATP. TNP-
ATP was applied for 1 min before and then during an application
of 3 WM ATP.
Fig. 5. The zP2X3 subunit can co-assemble with the rP2X2 subunit
to form a novel hetero-oligomeric receptor. ATP (1 WM) was ap-
plied for 1 s to a cell co-transfected with both the zP2X3 and rP2X2
subunits (left trace). This was followed 2 min later by a 1 s applica-
tion of 10 WM KL-meATP (middle trace). A subsequent 1 s applica-
tion of 1 WM ATP given an additional 2 min later (right trace)
demonstrates that the zP2X3/rP2X2 hetero-oligomeric receptor re-
covers from desensitization much quicker than the homo-oligomeric
zP2X3 receptor.
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homo-oligomeric rP2X2 as that receptor is insensitive to KL-
meATP. Therefore, the last two responses are due to the co-
assembly of zP2X3 and rP2X2 into a hetero-oligomeric recep-
tor. Thus, like the combination of rP2X2=3, it appears that the
zP2X3/rP2X2 combination manifests the pharmacological pro-
¢le of the P2X3 subunit. Unlike the mammalian pair, the
zebra¢sh subunit seems to retain the ability to exert some
in£uence over the desensitization properties of the hetero-olig-
omer, a property that may be re£ective of di¡erences in the
primary structures.
Although clearly the orthologue of the rat P2X3, the zebra-
¢sh cDNA described in this report encodes a protein with
enough di¡erences in primary structure to cause phenotypic
divergences as well. These ¢ndings help to lay the foundation
for future structure/function investigation into the pharmaco-
logical and biophysical properties of P2X subunits, and vali-
date the investigation of lower vertebrate gene products as a
means of aiding in the elucidation of P2X receptor function.
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